ArticleHepatitis monthly2016
Incidence and Risk Factors for Liver Abscess After Thermal Ablation of Liver Neoplasm.
Article in Hepatitis monthly, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Multimodal therapy and precision-imaging extends the limits of treatment for a patient with initially unresectable synchronous colorectal liver metastases.Annals of the Royal College of Surgeons of England · 2025Article
- Percutaneous thermal ablation in hepatocellular carcinoma patients with and without TIPS.Abdominal radiology (New York) · 2025Article
- Risk Reduction of Intrahepatic Abscess After Locoregional Therapy for Liver Cancer in Patients with Prior Hepatobiliary Intervention.Diagnostics (Basel, Switzerland) · 2025Review
- The microbiological features and risk factors for liver abscess after thermal ablation of liver cancer.Frontiers in cellular and infection microbiology · 2025Article
- Dispelling the Myths of Percutaneous Catheter Drainage of Infected Abdominal Collections.Seminars in interventional radiology · 2024Review
- Tumor complete response and pyogenic liver abscess secondary to concurrent microwave ablation plus atezolizumab and bevacizumab in liver cancer: a case report.Journal of gastrointestinal oncology · 2024Article
- Article
- Role of ablation therapy in conjunction with surgical resection for neuroendocrine tumors involving the liver.World journal of gastrointestinal surgery · 2024Article
- Introduction to interventional oncology: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatric blood & cancer · 2023Article
- Risk Factors for Abscess Development Following Percutaneous Microwave Ablation Therapy of Hepatic Tumors.Cardiovascular and interventional radiology · 2023Article
- Liver Abscess Formation After Laparoscopic Radiofrequency Ablation of Metastatic Colon Cancer.Cureus · 2022Article
- The frequency and risk factors of major complications after thermal ablation of liver tumours in 2,084 ablation sessions.Frontiers in surgery · 2022Article
- The Prevalence and Clinical Significance of Anaerobic Bacteria in Major Liver Resection.Antibiotics (Basel, Switzerland) · 2021Article
- The aura of malignant tumor: Clinical analysis of malignant tumor-related pyogenic liver abscess.Medicine · 2020Article
- Individualized Ablation of Hepatocellular Carcinoma: Tailored Approaches across the Phenotype Spectrum.Seminars in interventional radiology · 2019Review
- Septic Shock and Death after Microwave Ablation of Hepatocellular Carcinoma in a Liver Transplant Patient with a Bilioenteric Anastomosis.Seminars in interventional radiology · 2019Review
- Asymptomatic pyogenic liver abscesses secondary toBMJ case reports · 2017Article
- HepaticCase reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiofrequency ablation (RFA) and microwave ablation (MWA) are the most frequently used thermal ablation methods for the treatment of liver cancer. Liver abscess is a common and severe complication of thermal ablation treatment.
objectivesThe objective of this study was to determine the incidence and risk factors of liver abscess formation after thermal ablation of liver cancer. MATERIALS AND
methodsThe clinical data of 423 patients who underwent 691 thermal ablation procedures for liver cancer were collected in order to retrospectively analyze the basic characteristics, incidence, and risk factors associated with liver abscess formation. Patients with multiple risk factors for liver abscess formation were enrolled in a risk factor group, and patients with no risk factors were enrolled in a control group. The chi-square test and multiple logistic regression analysis were used to analyze the relationship between the occurrence of liver abscesses and potential risk factors.
resultsTwo hundred and eight patients underwent 385 RFA procedures, and 185 patients underwent 306 MWA procedures. The total incidence of liver abscesses was 1.7%, while the rates in the RFA group (1.8%) and MWA groups (1.6%) were similar (P > 0.05). The rates of liver abscesses in patients who had child-pugh class B and class C cirrhosis (P = 0.0486), biliary tract disease (P = 0.0305), diabetes mellitus (P = 0.0344), and porta hepatis tumors (P = 0.0123) were 4.0%, 6.7%, 6.5%, and 13.0%, respectively. There was a statistically significant difference between these four groups and the control group (all P < 0.05). The incidence of liver abscesses in the combined ablation and percutaneous ethanol injection (PEI) group (P = 0.0026) was significantly lower than that of the ablation group (P < 0.05).
conclusionsThe incidence of liver abscesses after liver cancer thermal ablation is low. Child-Pugh Class B and Class C cirrhosis, biliary tract disease, diabetes mellitus, and porta hepatis tumors are four significant risk factors. Combined ablation and PEI reduces the rate of liver abscesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.